CoreWeave Partners With AdaniConneX to Build 240MW AI Data Center in India
CoreWeave is partnering with AdaniConneX to build a 240-megawatt AI data center in Navi Mumbai, expanding its global footprint into India's growing market.
Company news
Every story explained in plain English, with the prices that matter beside it.
Amazon Expands Ring Smart Home Ecosystem With Keyless Deadbolt Lock
Amazon has unveiled a keyless Ring Smart Lock with a manual power backup to deepen its smart-home ecosystem and drive recurring subscription revenue.
Alzinova AB Raises SEK 44 Million in Rights Issue to Fund Phase II Trial
Alzinova AB has raised SEK 44 million after its rights issue was 86.2% subscribed, securing funds to transition its ALZ-101 program into Phase II.
CrowdStrike Shares Fall as Cybersecurity Firm Expands Startup Accelerator with Nvidia and AWS
CrowdStrike shares fell as the cybersecurity firm expanded its startup accelerator with Nvidia and AWS to boost applications built on its Falcon platform.
Zscaler Targets $8 Billion in ARR by 2031 as Analysts React with Mixed Outlooks
Zscaler outlines a path to $8 billion in organic annual recurring revenue by 2031, drawing mixed responses from analysts over growth and client acquisition.
Butterfly Network Partners With Bridge Neurotech on Ultrasound Brain Interface
Butterfly Network partners with Bridge Neurotech to develop ultrasound brain-computer interfaces, expanding its embedded technology portfolio.
Super Micro Computer Shares Rise on News of Lambda Funding Round
Super Micro Computer shares gained as AI infrastructure startup Lambda raises four billion dollars ahead of a planned initial public offering.
Eli Lilly Expands Protein Drug Discovery Deal With Gate Bioscience
Eli Lilly and Company expanded its drug-discovery partnership with Gate Bioscience in a deal that could reach $870 million to target difficult proteins.
Zealand Pharma Reports Positive Phase 2 Trial Results for Weight-Loss Drug Petrelintide
Zealand Pharma reported positive Phase 2 results for its weight-loss drug petrelintide, setting the stage for Phase 3 trials with partner Roche.
Chewy Lowers Chewy+ Annual Membership Fee to $59 to Attract More Subscribers
Chewy has cut its Chewy+ annual subscription fee to $59 to appeal to mid-spend customers and boost membership adoption as its stock faces pressure.
Caribou Biosciences Shares Plunge to All-Time Low Following Strategic Shift and Analyst Downgrades
Caribou Biosciences shares fell over 46% to an all-time low after halting key clinical programs and cutting jobs to explore strategic alternatives.
Air Products to Provide Malaysia's Inaugural LNG-Integrated Air Separation Facility
Air Products and Chemicals, Inc. is set to provide Malaysia's inaugural LNG-powered air separation facility, growing its presence in key regional hubs.
Alphonso Partners With Best Buy Ads to Offer LG TV Home Screen and CTV Video Inventory
Alphonso Inc. partners with Best Buy Ads to offer LG TV ad space, helping retail brands target shoppers using first-party purchase data.
Company newsNeutral
Air Products to Supply Malaysia's First LNG-Based Air Separation Unit for PETRONAS Gas Berhad Joint Venture
Air Products will supply Malaysia's first LNG-based air separation unit for a PETRONAS Gas Berhad joint venture, boosting regional efficiency.
LG Ad Solutions and Best Buy Partner to Bring Retail Ads to Smart TV Home Screens
Best Buy Co., Inc. partners with LG Ad Solutions to let advertisers target shoppers on smart TV home screens and track sales outcomes.
Seaport Therapeutics Doses First Patient in Phase 2a Trial for Anxiety Treatment
Seaport Therapeutics has dosed the first patient in a Phase 2a trial of GlyphAgo for generalized anxiety disorder and sleep disturbance.
Seaport Therapeutics Starts Phase 2a Trial of Anxiety Drug GlyphAgo
Seaport Therapeutics has dosed the first patient in a Phase 2a trial of GlyphAgo, an anxiety drug designed to reduce liver toxicity and improve sleep.
Pfizer Wins FDA Approval for TUKYSA as Front-Line Breast Cancer Maintenance Treatment
Pfizer (PFE) secured FDA approval for TUKYSA as a front-line breast cancer maintenance therapy, expanding its oncology revenue potential.
FDA Approves Pfizer's TUKYSA Combination for Front-Line Metastatic Breast Cancer
Pfizer's TUKYSA combination has been approved by the FDA as a front-line maintenance therapy to delay disease progression in HER2-positive breast cancer.
Valaris Secures $220 Million in New Offshore Drilling Contracts and Extensions
Valaris Ltd. secured offshore drilling contracts and extensions worth 220 million, boosting its backlog ahead of upcoming rig deployments.